Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
18,45 USD | +1,82 % | +1,65 % | +27,95 % |
Resumen de negocios
Número de empleados: 10 000
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Women's Health - Nexplanon/Implanon NXT
13,3
%
| 834 | 13,5 % | 830 | 13,3 % | -0,48 % |
Cardiovascular - Atozet
8,3
%
| 457 | 7,4 % | 519 | 8,3 % | +13,57 % |
Respiratory - Singulair
6,5
%
| 411 | 6,7 % | 404 | 6,5 % | -1,70 % |
Other - Other
5,1
%
| 326 | 5,3 % | 319 | 5,1 % | -2,15 % |
Cardiovascular - Zetia
4,9
%
| 357 | 5,8 % | 306 | 4,9 % | -14,29 % |
Cardiovascular - Cozaar/Hyzaar
4,5
%
| 323 | 5,2 % | 281 | 4,5 % | -13,00 % |
Biosimilars - Renflexis
4,4
%
| 226 | 3,7 % | 278 | 4,4 % | +23,01 % |
Other Non-opioid Pain, Bone and Dermatology
4,4
%
| 273 | 4,4 % | 275 | 4,4 % | +0,73 % |
Women's Health - Follistim AQ
4,2
%
| 229 | 3,7 % | 262 | 4,2 % | +14,41 % |
Non-opioid Pain, Bone and Dermatology - Arcoxia
4,1
%
| 241 | 3,9 % | 257 | 4,1 % | +6,64 % |
Respiratory - Nasonex
4,0
%
| 238 | 3,9 % | 253 | 4,0 % | +6,30 % |
Respiratory - Dulera
3,1
%
| 180 | 2,9 % | 194 | 3,1 % | +7,78 % |
Other Women's Health
2,7
%
| 204 | 3,3 % | 171 | 2,7 % | -16,18 % |
Non-opioid Pain, Bone and Dermatology - Fosamax
2,5
%
| 152 | 2,5 % | 159 | 2,5 % | +4,61 % |
Biosimilars - Ontruzant
2,5
%
| 122 | 2,0 % | 155 | 2,5 % | +27,05 % |
Other Cardiovascular
2,5
%
| 159 | 2,6 % | 155 | 2,5 % | -2,52 % |
Women's Health - NuvaRing
2,4
%
| 173 | 2,8 % | 152 | 2,4 % | -12,14 % |
Respiratory - Clarinex
2,2
%
| 125 | 2,0 % | 136 | 2,2 % | +8,80 % |
Women's Health - Marvelon/Mercilon
2,1
%
| 110 | 1,8 % | 134 | 2,1 % | +21,82 % |
Cardiovascular - Vytorin
2,1
%
| 130 | 2,1 % | 129 | 2,1 % | -0,77 % |
Other - Propecia
2,0
%
| 125 | 2,0 % | 125 | 2,0 % | 0,00 % |
Other
1,9
%
| 146 | 2,4 % | 121 | 1,9 % | -17,12 % |
Women's Health - Ganirelix Acetate Injection
1,8
%
| 123 | 2,0 % | 110 | 1,8 % | -10,57 % |
Other - Proscar
1,5
%
| 101 | 1,6 % | 97 | 1,5 % | -3,96 % |
Non-opioid Pain, Bone and Dermatology - Diprospan
1,5
%
| 122 | 2,0 % | 91 | 1,5 % | -25,41 % |
Other Respiratory
1,2
%
| 83 | 1,3 % | 77 | 1,2 % | -7,23 % |
Biosimilars - Brenzys
1,2
%
| 75 | 1,2 % | 73 | 1,2 % | -2,67 % |
Cardiovascular - Rosuzet
1,1
%
| 71 | 1,1 % | 70 | 1,1 % | -1,41 % |
Biosimilars - Hadlima
0,7
%
| 19 | 0,3 % | 44 | 0,7 % | +131,58 % |
Women's Health - Jada
0,7
%
| - | - | 43 | 0,7 % | - |
Biosimilars - Aybintio
0,7
%
| 39 | 0,6 % | 43 | 0,7 % | +10,26 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Europe and Canada
26,7
%
| 1 631 | 26,4 % | 1 673 | 26,7 % | +2,58 % |
United States
23,6
%
| 1 437 | 23,3 % | 1 478 | 23,6 % | +2,85 % |
Asia Pacific and Japan
18,0
%
| 1 143 | 18,5 % | 1 129 | 18,0 % | -1,22 % |
Latin America, Middle East, Russia and Africa
15,4
%
| 895 | 14,5 % | 965 | 15,4 % | +7,82 % |
China
13,8
%
| 917 | 14,9 % | 864 | 13,8 % | -5,78 % |
Global
2,5
%
| 151 | 2,4 % | 154 | 2,5 % | +1,99 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Kevin Ali
CEO | Chief Executive Officer | 63 | 02/06/21 |
Matthew Walsh
DFI | Director of Finance/CFO | 57 | 02/06/21 |
Chief Tech/Sci/R&D Officer | 54 | 05/09/23 | |
Rachel Stahler
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/01/21 |
Marcel van Duin
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/22 |
Jennifer Halchak
IRC | Investor Relations Contact | - | - |
Charlotte Owens
PRN | Corporate Officer/Principal | - | 05/09/23 |
Kirke Weaver
LAW | General Counsel | - | 01/07/22 |
Vittorio Nisita
PRN | Corporate Officer/Principal | 56 | 02/06/21 |
Joseph Morrissey
PRN | Corporate Officer/Principal | 59 | 02/06/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Rochelle Lazarus
BRD | Director/Board Member | 76 | 02/06/21 |
Carrie Cox
CHM | Chairman | 66 | 02/06/21 |
Robert Essner
BRD | Director/Board Member | 76 | 02/06/21 |
Helene Gayle
BRD | Director/Board Member | 69 | 02/06/21 |
Shalini Sharp
BRD | Director/Board Member | 49 | 02/06/21 |
Director/Board Member | 70 | 02/06/21 | |
Philip Ozuah
BRD | Director/Board Member | 61 | 02/06/21 |
Grace Whiteford
BRD | Director/Board Member | 61 | 02/06/21 |
Director/Board Member | 55 | 02/06/21 | |
Kevin Ali
CEO | Chief Executive Officer | 63 | 02/06/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 255 638 256 | 255 342 706 ( 99,88 %) | 0 | 99,88 % |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Pharmaceuticals: Major
| |
Organon (India) Pvt Ltd.
Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India. |
Pharmaceuticals: Major
|
Dashtag
Dashtag Financial ConglomeratesFinance Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK. |
Financial Conglomerates
|
GTS FI BV
GTS FI BV Financial ConglomeratesFinance Part of Organon & Co., GTS FI BV is an investment holding Dutch company that provides financing services. The private company is located in Netherlands. |
Financial Conglomerates
|
Organon Finance 1 LLC
|
Finance/Rental/Leasing
|
Organon LLC
| |
Organon Foreign Debt Co-Issuer BV
|
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+27,95 % | 4716,53 M | |
+33,50 % | 701 mil M | |
+26,24 % | 571 mil M | |
+0,78 % | 381 mil M | |
+20,85 % | 334 mil M | |
+16,38 % | 319 mil M | |
+2,20 % | 210 mil M | |
+1,34 % | 210 mil M | |
-6,44 % | 201 mil M | |
-3,51 % | 157 mil M |
- Bolsa
- Acciones
- Acción Organon & Co. - Nyse
- Empresa Organon & Co.